IntelliPharmaCeutics strength lies in its dynamic product pipeline. Present pipeline products, all of which are available for mid to late stage licensing, include new drugs (NDA's) designed to extend the life of, improve upon or replace existing branded drugs, and bio-equivalents (ANDA's) of successful branded controlled release drugs. Based upon the Company's track record, the chances of successful development of these products are excellent.

IntelliPharmaCeutics' track record in designing and developing controlled release drug products for its clients is second to none. A substantial proportion of the bio-equivalent controlled release products in the U.S. market today were designed and developed by the Company's scientists and now enjoy strong sales in the demanding U.S. market. Past successes also include NDA's in advanced stages of clinical trials, and controlled release products with accepted FDA filings now awaiting approval.

For more information contact Yogish Kamath, Director of New Business Development at ykamath@intellipharmaceutics.com